Core Viewpoint - Sotera Health is focused on safeguarding global health through its three business segments: Sterigenics, Nordion, and Nelson Labs, serving over 5,000 customers in 50 countries with a workforce of more than 3,100 employees [3]. Group 1: Company Overview - Sotera Health derives its name from the Greek goddess of safety, reflecting its mission to ensure health safety globally [3]. - The company operates through three main business units: Sterigenics, Nordion, and Nelson Labs, providing comprehensive solutions in the healthcare sector [3]. Group 2: Financial Performance - The presentation emphasizes the strong and consistent financial performance of Sotera Health over many years, indicating a stable growth trajectory [2]. Group 3: Long-term Value Creation - The discussion includes a focus on the company's strategy for driving long-term value for shareholders, highlighting its commitment to sustainable growth and shareholder returns [2].

Summary of Sotera Health Company FY Conference Call Company Overview - **Company Name**: Sotera Health Company (NasdaqGS:SHC) - **Mission**: Safeguarding global health through its three business units: Sterigenics, Nordion, and Nelson Labs [2][3] - **Global Presence**: Over 5,000 customers in 50 countries, 3,100 employees, and 62 facilities across 13 countries [3] - **Customer Base**: Engages with 40 of the top 50 medical device companies and 9 of the top 10 pharmaceutical companies [3] Business Segments Sterigenics - **Largest Business Unit**: Represents about two-thirds of the company's revenue [4] - **EBITDA Margins**: Approximately 50% [4] - **Sterilization Methods**: 39% ethylene oxide, 49% gamma, and 12% eBeam [5] - **Service Model**: Operates as a service business, where customers drop off products for sterilization [5] Nordion - **Product Business**: World's largest provider of Cobalt-60, critical for sterilization [6] - **EBITDA Margins**: Approximately 60% [7] - **Cobalt Sourcing**: Obtains Cobalt-60 from reactors in multiple countries including China, Canada, and Russia [6] Nelson Labs - **Testing Services**: Leader in microbiological and analytical chemistry testing with about 3,000 customers [7] - **Revenue Composition**: 48% routine testing, 37% validation, and 15% advisory services [8] Financial Performance - **Revenue Growth**: Surpassed $1.16 billion in revenue, with a minimum growth of over 5% [10] - **CAGR**: 7% growth in top line and adjusted EBITDA since going public in 2020 [11] - **Free Cash Flow**: Targeting $500 million to $600 million in cumulative free cash flow from 2025 to 2027 [20] - **Leverage Ratio**: Aiming to reduce net leverage from 3.3 times to a target of 2-3 times [12] Strategic Priorities 1. **Customer Service Excellence**: Focus on providing end-to-end solutions [13] 2. **Growth Market Segmentation**: Targeting high-growth segments within med tech and pharma [14] 3. **Operational Excellence**: Enhancing free cash flow through disciplined capital deployment [15] 4. **Long-term Value Creation**: Aiming for consistent top-line growth of 5%-7% annually [17] Market Outlook - **Growth Projections**: Sterigenics expected to grow mid-single to high-single digits, Nelson Labs mid-single digits, and Nordion low-single to mid-single digits [18] - **Pricing Strategy**: Anticipating a price increase of 3%-4% across the company [30] Regulatory Environment - **NESHAP Standards**: New regulations for ethylene oxide have been extended to April 2028, impacting smaller competitors [33] - **Litigation Updates**: Favorable rulings in Georgia regarding ethylene oxide litigation, with ongoing cases in California [52][54] Investment Rationale - **Market Position**: Leader in a growing $18 billion addressable market with strong margins and cash flow [24] - **Regulatory Expertise**: Established expertise in navigating highly regulated markets [24] - **Growth Potential**: Continued investment in capacity and operational improvements expected to drive future growth [25] Conclusion - **Company Confidence**: Strong execution and commitment to delivering growth and cash flow, positioning Sotera Health as a compelling investment opportunity for the future [55]

2026 J.P. Morgan Healthcare Conference Safeguarding Global Health® Michael B. Petras, Jr. Chairman and Chief Executive Officer January 12, 2026 © 2026 Sotera Health Company | All Rights Reserved. Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subs ...

Financial Results - Sotera Health Company announced preliminary revenue results for full-year 2025, which are within the guidance provided during the third quarter earnings release[8]. - The preliminary revenue results are subject to completion of year-end financial closing procedures and audit by the independent registered public accounting firm[8]. - The financial results are being disclosed under Item 2.02 and Item 7.01 of the SEC filing[10]. - The press release detailing the preliminary financial results was issued on January 12, 2026[6]. Company Information - The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol SHC[2]. - The address of the principal executive offices is 9100 South Hills Blvd, Suite 300, Broadview Heights, Ohio 44147[2]. - The company has not indicated any changes to its status as an emerging growth company[4]. Upcoming Events - The company will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026[9]. Document Details - The report was signed by Jonathan M. Lyons, Senior Vice President and Chief Financial Officer[13]. - The press release is attached as Exhibit 99.1 in the SEC filing[11].

Core Viewpoint - Sotera Health Company is experiencing solid growth, with revenue expected to exceed $1.16 billion in 2025, marking a year-over-year increase of at least 5.5% [2] Group 1: Company Overview - Sotera Health is a leading global provider of end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [6] - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [6] - The mission of Sotera Health is to safeguard global health [6] Group 2: Financial Performance - Revenue for 2025 is projected to surpass $1.16 billion, reflecting a growth of at least 5.5% year-over-year or 5.0% on a constant-currency basis [2] - This growth marks over two decades of consecutive year-over-year revenue increases, demonstrating the durability of the company's business model and financial profile [2] - Full-year results and the 2026 outlook will be shared on February 24, 2026 [2] Group 3: Investor Relations - A live webcast of the company's presentation at the J.P. Morgan Healthcare Conference will be available on the Investor Relations section of the company's website [2] - A replay of the presentation will be accessible within 48 hours and archived on the company's website [2]

Core Insights - The transaction involved Warburg Pincus & Co. selling 9,720,000 shares of Sotera Health Company at approximately $16.33 per share, totaling $158,727,600, which represents a significant reduction in their indirect stake [4][7]. Company Overview - Sotera Health Company is a prominent provider of sterilization and lab testing services, with a diverse customer base in healthcare and life sciences, leveraging advanced technology and regulatory expertise to ensure product safety and compliance [6]. Transaction Details - The sale was executed through indirect entities, specifically Bull Holdco L.P. and Bull Co-Invest L.P., with Warburg Pincus holding no direct shares before or after the transaction [3][5]. - The 9,720,000 shares sold accounted for 22.18% of Warburg Pincus's indirect stake, leaving them with 34,102,952 shares indirectly held post-transaction [4]. Market Performance - As of January 8, 2026, Sotera Health's stock has increased nearly 40% year over year, with consistent sales growth reported in seven out of the last eight quarters and earnings growth in the latest three quarters [7]. - The stock price was $16.84 at market close on the day of the transaction, reflecting a year-over-year increase of 31.25% as of December 3, 2025, indicating favorable liquidity conditions for the sale [1][7]. Institutional Ownership - Warburg Pincus, a global private equity firm, holds a significant investment in Sotera Health, owning 48% of the company, and has three seats on its board of directors [8][9]. - The presence of institutional investors like Warburg Pincus can signal potential upside for retail investors, despite the recent sale raising some concerns [9].

Core Viewpoint - Sotera Health Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its role as a leading provider of sterilization solutions and lab testing services for the healthcare industry [1]. Group 1 - Sotera Health is recognized as a global leader in providing mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare sector [3]. - The company operates through three main business units: Sterigenics®, Nordion®, and Nelson Labs® [3]. - The company is dedicated to its mission of "Safeguarding Global Health®" [3]. Group 2 - A live webcast of the presentation will be accessible on the Investor Relations section of the company's website, with a replay available within 48 hours [2]. - Updates relevant to investors can be found in the Investor Relations section of the company's website [4].

Summary of Sotera Health Company FY Conference Call Company Overview - **Company**: Sotera Health Company (NasdaqGS:SHC) - **Date of Conference**: December 03, 2025 Key Industry Insights - **Market Normalization**: The med tech industry is experiencing consistent volume expansion across various customer types, indicating a normalized market without significant transient factors affecting volumes [1][2] - **Outsourcing Trends**: Approximately two-thirds of the sterilization market is outsourced, with a gradual shift towards outsourcing over multiple years, but no significant year-to-year changes are observed [5][6] - **NSHAP Regulations**: The new NSHAP regulations regarding sterilizers, particularly ethylene oxide, are expected to take effect in April 2026, but concerns about compliance have diminished due to extensions [7][9] Company Performance and Strategy - **Capacity Management**: The company is cautious about capital investments in new sterilization capacity, ensuring that new facilities are justified by demand and customer commitments [14][16] - **Future Capacity Plans**: New facilities are expected to come online in late 2026 and 2027, with a strategy to secure about 40% of capacity commitments before construction [16][18] - **Pricing Power**: The company anticipates maintaining a price increase of 3%-4% annually, with Sterigenics positioned at the higher end of this range due to multi-year contracts [21][22] Financial Outlook - **Capital Expenditure (CapEx)**: Current CapEx is elevated due to cobalt development and NSHAP compliance, but is expected to decrease to around $100 million in the long term [22][23] - **Debt Management**: The company aims to reduce net leverage to 2-3 times by the end of 2027, while generating $500-$600 million in free cash flow during the same period [27][30] - **Cash Allocation**: Priorities for cash allocation include organic growth, debt reduction, and potential M&A opportunities, with a focus on maintaining a strong balance sheet [31][32] Business Segments - **Nordion**: The Cobalt-60 business is a significant cash generator with a 60% margin, providing essential sterilization services and maintaining a strong market position [35][36] - **Nelson Labs**: The testing business is crucial for regulatory compliance and product marketability, with a focus on sterility assurance and cross-business synergies with Sterigenics [38][39][40] Litigation and Risk Management - **Litigation Status**: The company has made progress in de-risking its litigation profile, particularly concerning ethylene oxide cases, with confidence in scientific evidence supporting its position [43][44] Conclusion - Sotera Health Company is well-positioned in the med tech industry, with a focus on maintaining growth, managing capacity, and navigating regulatory challenges while ensuring strong financial health and strategic investments in its core businesses.

Sotera Health Company Conference Summary Company Overview - **Company Name**: Sotera Health Company - **Ticker**: NasdaqGS:SHC - **Date of Conference**: November 19, 2025 - **CEO**: Michael Petras - **Business Structure**: Comprises three entities: Sterigenics, Nordion, and Nelson Labs - **Global Presence**: Approximately 5,000 customers in over 50 countries, with 62 facilities worldwide and over 3,000 employees [3][4][5] Core Business Insights - **Sterigenics**: Largest business segment, a global leader in sterilization services for medtech and pharma industries. Utilizes gamma radiation, ethylene oxide, and E-beam sterilization methods [4][6][9] - **Nordion**: Unique product business providing cobalt-60 for sterilization, with a recently renewed 25-year site license in Ottawa, Canada [7][8] - **Nelson Labs**: Focuses on microbiology and analytical chemistry testing, serving the same customer base as Sterigenics [8][9] Financial Performance - **Growth Metrics**: - 7% CAGR on both top line and bottom line since going public in 2020 - Recent quarter: 9% top line growth, 12.2% adjusted EBITDA growth, and adjusted EPS of $0.09 [9][10] - Year-to-date: 6% top line growth, 10% adjusted EBITDA growth, and adjusted EPS of $0.11 [10] - **Liquidity**: Approximately $900 million in liquidity with a net leverage ratio of about 3.3 times [10] Strategic Priorities - **Customer Service Excellence**: Focus on end-to-end solutions and cross-business collaboration, with over 40% of Nelson Labs business tied to sterility assurance [11][12] - **Market Growth**: Targeting mid to high single-digit organic growth across all business segments, with a long-range plan of 5-7% growth from 2025 to 2027 [12][13] - **Operational Excellence**: Emphasis on enhancing free cash flow and disciplined capital allocation, with a focus on growth investments in cobalt-60 development [12][14] Capital Allocation and M&A Strategy - **Capital Deployment**: Majority focused on CapEx for growth investments, particularly in cobalt-60 development [13][14] - **M&A Outlook**: Open to strategic acquisitions, particularly in Sterigenics and Nordion, while ensuring stability in Nelson Labs [34][35] Market Dynamics - **Competitive Landscape**: Nelson Labs operates in a fragmented market with many competitors, but differentiates itself through a focus on med device and pharma testing [31][32] - **Regulatory Influence**: New regulations drive demand for Nelson Labs' services, particularly in helping customers meet compliance [32][33] Future Outlook - **Growth Projections**: Anticipated growth of 5-7% on the top line and 5-8% on the bottom line from 2025 to 2027, with expected free cash flow of $500 million to $600 million over the same period [15][17] - **Market Positioning**: Strong customer relationships and a global network of facilities position the company well for future growth [16][17] Additional Insights - **Capacity Expansion**: Ongoing investments in capacity to support growth, including new facilities for X-ray sterilization [21][22] - **Inventory Management**: Improved stability in customer inventory levels is expected to enhance growth in the Sterigenics business [39][41] - **Bioprocessing Growth**: Although a small percentage of total business, bioprocessing is showing growth, influenced by new regulatory requirements [43][44]

Financial Performance - For the three months ended September 30, 2025, total net revenues increased by $25.8 million, or 9.1%, to $311.3 million compared to $285.5 million in the same period of 2024[170]. - Net income for the three months ended September 30, 2025 was $48.4 million, a significant increase of $31.4 million, or 184.7%, from $17.0 million in the same period of 2024[170]. - Adjusted Net Income for the three months ended September 30, 2025 was $75.3 million, up $26.3 million, or 53.8%, from $48.9 million in the same period of 2024[170]. - Adjusted EBITDA for the three months ended September 30, 2025 was $164.2 million, an increase of $17.8 million, or 12.2%, compared to $146.4 million in the same period of 2024[170]. - For the nine months ended September 30, 2025, total net revenues were $860.2 million, an increase of $49.9 million, or 6.2%, compared to $810.2 million in the same period of 2024[190]. - Adjusted EBITDA for the nine months ended September 30, 2025 was $436.8 million, an increase of $41.1 million, or 10.4%, from $395.6 million in the same period of 2024[190]. - Net income for the nine months ended September 30, 2025, was $43.1 million, compared to $32.1 million for the same period in 2024, while Adjusted Net Income rose to $170.4 million from $139.8 million[210]. Revenue Breakdown - Service revenues for the three months ended September 30, 2025 increased by $16.7 million, or 7.0%, to $255.5 million, driven by volume increases in the Sterigenics and Nordion segments[173]. - Product revenues for the three months ended September 30, 2025 rose by $9.1 million, or 19.5%, to $55.8 million, primarily due to higher revenues from Co-60 in the Nordion segment[174]. - Service revenues increased by $33.7 million, or 4.8%, to $736.7 million for the nine months ended September 30, 2025, compared to $703.0 million for the same period in 2024, driven by favorable pricing and volume/mix improvements[193]. - Product revenues rose by $16.3 million, or 15.2%, to $123.5 million for the nine months ended September 30, 2025, compared to $107.2 million in the prior year, primarily due to favorable volume/mix and pricing in the Nordion segment[194]. - Sterigenics segment net revenues increased by $17.3 million, or 9.8%, to $192.8 million for the three months ended September 30, 2025, driven by a 4.6% increase in volume and mix[218]. - Nordion segment net revenues increased by $11.5 million, or 22.4%, to $62.8 million for the three months ended September 30, 2025, primarily due to an 18.9% increase in volume and mix[219]. - Nelson Labs segment net revenues decreased by $2.9 million, or 5.0%, to $55.7 million for the three months ended September 30, 2025, impacted by a decline in expert advisory services revenue[220]. - Sterigenics net revenues increased by $38.9 million, or 7.5%, to $557.4 million for the nine months ended September 30, 2025, driven by favorable pricing and volume impacts[225]. - Nordion net revenues rose by $21.2 million, or 18.2%, to $137.8 million, primarily due to volume and mix changes of 16.7% and pricing of 3.1%[226]. - Nelson Labs net revenues decreased by $10.2 million, or 5.8%, to $165.0 million, impacted by a decline in expert advisory services revenue despite growth in core lab testing services[227]. Expenses and Costs - Total cost of revenues for the three months ended September 30, 2025 was $133.8 million, an increase of $6.3 million, or 4.9%, from $127.4 million in the same period of 2024[170]. - SG&A expenses increased by $1.3 million, or 2.1%, for the three months ended September 30, 2025, attributed to higher litigation and professional services expenses[180]. - Total cost of revenues increased by $8.3 million, or 2.2%, to $380.6 million for the nine months ended September 30, 2025, accounting for approximately 44.2% of consolidated net revenues[196]. - SG&A expenses increased by $14.5 million, or 8.0%, for the nine months ended September 30, 2025, mainly due to a $15.2 million increase in litigation and professional services expenses[199]. Cash Flow and Capital Expenditures - As of September 30, 2025, the company had $299.2 million of unrestricted cash, an increase of $22.0 million from December 31, 2024, due to $184.1 million in cash flows from operating activities[240]. - Capital expenditures for the nine months ended September 30, 2025, amounted to $87.3 million, down from $113.2 million in the same period of 2024[242]. - Net cash provided by operating activities was $184.1 million for the nine months ended September 30, 2025, compared to $168.4 million for the same period in 2024[243]. - Cash flows from operating activities increased by $15.6 million to $184.1 million for the nine months ended September 30, 2025, compared to $168.4 million for the same period in 2024[245]. - Cash used in investing activities decreased by $28.7 million to $84.4 million for the nine months ended September 30, 2025, compared to $113.1 million for the same period in 2024, primarily due to a $25.9 million decrease in capital expenditures[246]. - Cash used in financing activities increased by $48.3 million to $92.4 million for the nine months ended September 30, 2025, compared to $44.0 million for the same period in 2024, mainly due to an $81.3 million increase in principal repayments on Term Loans[247]. Debt and Financial Obligations - As of September 30, 2025, the company had debt obligations of $1,423.0 million under a term loan, a $600.0 million revolving credit facility, and $750.0 million of senior notes[248]. - Amendment No. 6 to the Credit Agreement reduced the interest rate margin by 0.50% and provided for refinancing lenders to offer term loans totaling $1,423.0 million[250]. - The company had $8.1 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability of $591.9 million[255]. - The company utilizes interest rate derivatives to manage cash flow variability associated with variable rate debt[256]. Market and Accounting Policies - There have been no significant changes in critical accounting policies or management estimates since December 31, 2024[257]. - Market risks have not materially changed for the three and nine months ended September 30, 2025[259].